Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.

The FAS-FASL system plays crucial role in counterattack of cancer cell against immune system. This study examined the effects of FAS (-1377G/A and -670A/G) and FASL (-844T/C and 7896G/C) polymorphisms on breast cancer risk and apoptosis of T lymphocytes. The effect on breast cancer risk was determined by case-control analysis of 840 patients and 840 controls. The effects on T-lymphocyte apoptosis were determined by activation-induced cell death (AICD) of T cells ex vivo and by analyzing apoptotic tumor-infiltrating lymphocytes (TILs) in breast cancer tissue. We found moderately increased risk associated with FAS -1377AG [odds ratio (OR), 1.29; 95% confidence interval (CI), 1.05-1.59] and -1377AA (OR, 1.36; 95% CI, 1.01-1.82) genotypes compared with the -1377GG genotype and decreased risk associated with FASL -844CT (OR, 0.76; 95% CI, 0.62-0.94) and -844TT (OR, 0.66; 95% CI, 0.43-1.00) genotypes compared with the -844CC genotype. T lymphocytes with the FASL -844CC genotype had heightened FASL expression that is associated with increased AICD of the T cells stimulated by MCF-7 cells or phytohemagglutinin compared with the FASL -844TT genotype (10.38 +/- 4.09% and 24.29 +/- 1.50% versus 6.03 +/- 0.41% and 17.96 +/- 3.66%; P < 0.05 and 0.001). Breast cancer patients with the FASL -844CC genotype had higher apoptotic TILs in their cancer tissues than those with the FASL -844TT genotype (33.7 +/- 1.2% versus 19.1 +/- 2.0%; P = 0.007). These findings indicate that functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.

[1]  W. Tan,et al.  FASL –844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer , 2005, The Journal of experimental medicine.

[2]  Y. Hung,et al.  Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. , 2005, Gynecologic oncology.

[3]  W. Tan,et al.  Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer , 2005, Journal of Medical Genetics.

[4]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[5]  W. Tan,et al.  Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma. , 2004, Carcinogenesis.

[6]  U. Langsenlehner,et al.  Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. , 2004, Journal of the National Cancer Institute.

[7]  M. Beckmann,et al.  Awareness of breast cancer incidence and risk factors among healthy women , 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[8]  W. Tan,et al.  Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. , 2004, Journal of the National Cancer Institute.

[9]  M. Spitz,et al.  Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. , 2003, Lung cancer.

[10]  Alexandra G. Smith,et al.  Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. , 2003, Cancer research.

[11]  D. Green,et al.  Activation‐induced cell death in T cells , 2003, Immunological reviews.

[12]  G. Cooper,et al.  A Novel Polymorphic CAAT/Enhancer-Binding Protein β Element in the FasL Gene Promoter Alters Fas Ligand Expression: A Candidate Background Gene in African American Systemic Lupus Erythematosus Patients1 , 2003, The Journal of Immunology.

[13]  W. Zheng,et al.  Occupations and breast cancer risk among Chinese women in urban Shanghai. , 2002, American journal of industrial medicine.

[14]  P. Krammer,et al.  Immune escape of tumors: apoptosis resistance and tumor counterattack , 2002, Journal of leukocyte biology.

[15]  S. Maher,et al.  Activation‐induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack , 2002, Immunology and cell biology.

[16]  J. Russell,et al.  The regulation of FasL expression during activation‐induced cell death (AICD) , 2001, Immunology.

[17]  G. Evan,et al.  Proliferation, cell cycle and apoptosis in cancer , 2001, Nature.

[18]  A. Frey,et al.  CD8+ Tumor-Infiltrating Lymphocytes Are Primed for Fas-Mediated Activation-Induced Cell Death But Are Not Apoptotic In Situ1 , 2001, The Journal of Immunology.

[19]  J. Fraumeni,et al.  Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  J. Hall,et al.  The ATM gene and breast cancer: is it really a risk factor? , 2000, Mutation research.

[21]  M. Mottolese,et al.  Prognostic relevance of altered Fas (CD95)‐system in human breast cancer , 2000, International journal of cancer.

[22]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[23]  T. Reimer,et al.  FasL:Fas ratio--a prognostic factor in breast carcinomas. , 2000, Cancer research.

[24]  M. Beckmann,et al.  CD95 ligand expression as a mechanism of immune escape in breast cancer , 2000, Immunology.

[25]  S. Coughlin,et al.  Genetic polymorphisms and risk of breast cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  B. Ponder,et al.  A Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk 1 , 2000 .

[27]  G. Mor,et al.  The Fas/Fas‐ligand system: a mechanism for immune evasion in human breast carcinomas , 1999, Breast Cancer Research and Treatment.

[28]  S. Rosenberg,et al.  Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. , 1999, Journal of immunology.

[29]  N. Restifo,et al.  T cell–tumor cell: a fatal interaction? , 1998, Cancer Immunology, Immunotherapy.

[30]  C. Brady,et al.  The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. , 1998, Journal of immunology.

[31]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[32]  C Zapata,et al.  Approximate variance of the standardized measure of gametic disequilibrium D'. , 1997, American journal of human genetics.

[33]  N. Manolios,et al.  Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. , 1997, Molecular immunology.

[34]  T. Griffith,et al.  The role of FasL-induced apoptosis in immune privilege. , 1997, Immunology today.

[35]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[36]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[37]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[38]  W. Willett,et al.  Risk of breast cancer in relation to lifetime alcohol consumption. , 1995, Journal of the National Cancer Institute.

[39]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[40]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[41]  T. Pohl,et al.  Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. , 1993, Immunology today.

[42]  H. Morgenstern,et al.  Epidemiologic Research: Principles and Quantitative Methods. , 1983 .

[43]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[44]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[45]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[46]  S. Koyama,et al.  Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma , 2001, Journal of Cancer Research and Clinical Oncology.

[47]  K. Ebeling,et al.  [Epidemiology of breast cancer]. , 1988, Archiv fur Geschwulstforschung.